GlucoTrack, Inc.
GCTK
Last
$1.05
Day
-5.4%
1y
-99.1%
5y
-100.0%
52w
-99.1%
SPY YTD
+13.3%
XLV
+8.1%
Earnings
2026-11-1233d
EMA 21
1.93
EMA 50
3.39
EMA 200
284.70
20d high
-65.8%
5y high
-100.0%
5y range
0th
Positions held
Your positionsGCTK isn't in your positions.
Add it to see shares, cost, and P&L here.
Score
-6
Hold
avoid
Signal
Sell
Target
$1.65
Stop
$0.66
Stop distance
37.1%
Target vs last
+57.1%
Fundamentals
| Market cap | $1.13M | Enterprise value | $1.62M | Trailing P/E | — | Forward P/E | — |
| PEG | — | Price / book | -0.27 | Beta | 0.73 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -6.2% | ROA | -1.6% | Debt / equity | — |
| Current ratio | 0.46 | Free cash flow | -$10.39M | Analyst recommendation | none | Mean target | — |
| 52w high | $125.25 | 52w low | $1.07 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$3.8M | -$4.3M | -$3.6M | -$4.2M | -$4.8M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$3.4M | -$4.2M | -$3.5M | -$4.3M | -$4.8M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$19.4M | -$22.6M | -$7.1M | -$4.4M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$16.1M | -$14.5M | -$7.1M | -$4.4M | — |
Headline scan
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-25 · Lōkahi Therapeutics™ Expands ai2 Pipeline™ Program Through Collaboration with Pepperdine E2B™
2026-09-24 · BC-Most Active Stocks
2026-09-24 · Glucotrack, Inc. Announces Pricing of $3 Million Public Offering
2026-09-11 · Glucotrack Announces $11.5 Million Financing
2026-09-08 · Lōkahi Therapeutics™ Expands ai² Into Three Opportunity-Creating Business Divisions
2026-08-27 · Glucotrack, Inc. Announces Reverse Stock Split
Price (daily)
Full chart · RSI · MACD · patternsGCTK · daily-50.0% over 13 sessions
Close EMA21 EMA50 EMA200
Quarterly · revenue, net income, margins
Revenue Net income Gross margin Op margin